Innovating chemistry

Philochem develops anti-cancer products of unprecedented potency and selectivity, thanks to excellence in encoded combinatorial chemistry.

Philochem is a Swiss subsidiary of the Philogen group, acting as discovery center with a focus on chemical pharmaceutical products and technologies.

Nov 28 2025
,

2026 Swiss Chemical Society (SCS) Industrial Science Award for Samuele Cazzamalli, Head of Research at Philochem

Dr. Samuele Cazzamalli, Head of Research at Philochem, will be awarded the Industrial Science Award 2026 from the Swiss Chemical Society His research has focused on the...
Oct 01 2025
,

Philochem to attend the Festival of Biologics 2025 in Basel on September 30-October 2, 2025

Dr. Emanuele Puca will give an oral presentation entitled: “Antibody-cytokine Fusions for Cancer Therapy: Late-Stage Clinical Results” Dr. Roberto de Luca will give an...
Aug 18 2025
,

Philochem AG Announces Completion of Antitrust Clearance and Closing of the OncoACP3 Licensing Agreement with RayzeBio, a Bristol Myers Squibb Company, With a Potential Value of up to $1.35 Billion Plus Royalties

For more details
Jun 11 2025
,

Philogen is pleased to invite you to a webinar with Prof. Dario Neri, taking place today, June 11, at 11:00 ET | 17:00 CET.

Following last night's announcement regarding OncoACP3, we are pleased to invite you to a webinar with Prof. Dario Neri, taking place today, June 11, at 11:00 ET |...
Jun 10 2025

Philochem AG Announces the Licensing of Worldwide Rights to OncoACP3, a novel Radiopharmaceutical Therapeutic and Diagnostic Agent targeting Prostate Cancer, to RayzeBio, a Bristol-Myers Squibb Company, for a potential value of up to $1.35bn plus royalties.

More details
Mar 22 2025

Philogen to attend the Swiss Radiopharmacy Day on March 21, 2025

Our certified radiation protection experts, Dr. Jacqueline Mock and Dr. Sebastian Oehler, will take part and represent Philochem in the Swiss Radiopharmacy Day.
Mar 22 2025
,

Philogen to attend the PEGS Boston 2025 on May 13-16, 2025

Dr. Sebastian Oehler will present Philochem’s recent discovery in the field of prostate cancer under the title “From DNA-Encoded Chemistry to ACP3-Targeted Radioligand...
Mar 22 2025
,

Philogen to attend AACR 2025 on April 25-30, 2025

Claudia Comacchio is presenting a poster about Philochem’s ACP3 antibody therapeutics on April 29, entitled “Generation and in vivo characterization of a novel antibody...
Sep 04 2024
, ,

2024 EFMC Prize for Young Medicinal Chemist or Chemical Biologist in Industry for Samuele Cazzamalli, Head of Chemistry at Philochem

Dr. Samuele Cazzamalli, Head of Chemistry at Philochem, will be awarded the 2024 EFMC Prize for Young Medicinal Chemist or Chemical Biologist in Industry....
Feb 21 2024
,

Philochem AG announces Board of Appeal decision on Philochem’s Patent on Production of Encoded Chemical Libraries

More details

OUR SCIENCES

Learn about our strategy

PIPELINE

Learn more about our pipeline

WORK WITH US

Look at open positions